Proteasome inhibitor MG132 suppresses number and function of endothelial progenitor cells: Involvement of nitric oxide synthase inhibition

International Journal of Molecular Medicine

Volumn 25, Issue 3, 2010, Pages 385-392

  Hu, Xiao Sheng ^a   Du, Chiang Qing ^a   Yang, Lin ^a   Yao, Xue Yan ^a   Hu, Shen Jiang ^a  

^a ZHEJIANG UNIVERSITY   (China)

Author keywords

Cell number and function; Endothelial nitric oxide synthase nitric oxide; Endothelial progenitor cells; Proteasome inhibitor

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; BENZYLOXYCARBONYLLEUCYLLEUCYLLEUCINAL; ENDOTHELIAL NITRIC OXIDE SYNTHASE; LECTIN; LIPOCORTIN 5; NITRIC OXIDE; PROPIDIUM IODIDE; PROTEASOME INHIBITOR;

APOPTOSIS; ARTICLE; BINDING ASSAY; CELL ADHESION; CELL ASSAY; CELL COUNT; CELL CULTURE; CELL ISOLATION; CELL MIGRATION; CELL PROLIFERATION; CELL STIMULATION; COLONY FORMATION; CONCENTRATION RESPONSE; CONFOCAL LASER MICROSCOPY; CONTROLLED STUDY; DENSITY GRADIENT CENTRIFUGATION; ENDOTHELIAL PROGENITOR CELL; ENZYME INHIBITION; FLUORESCENCE ANALYSIS; HUMAN; HUMAN CELL; MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; STEM CELL; WESTERN BLOTTING;

ADULT; APOPTOSIS; CELL ADHESION; CELL MOVEMENT; CELL PROLIFERATION; CYSTEINE PROTEINASE INHIBITORS; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDOTHELIAL CELLS; HUMANS; LEUPEPTINS; NITRIC OXIDE; NITRIC OXIDE SYNTHASE TYPE III; PROTEASOME ENDOPEPTIDASE COMPLEX; STEM CELLS;

EID: 76949096759     PISSN: 11073756     EISSN: 1791244X     Source Type: Journal    
DOI: 10.3892/ijmm_00000356     Document Type: Article

References (46)

1. Asahara T, Murohara T, Sullivan A, Silver M, van der Zee R, Li T, Witzenbichler B, Schatteman G and Isner JM: Isolation of putative endothelial progenitor cells for angiogenesis. Science 275: 964-967, 1997.
2. Walter DH, Rittig K, Bahlmann FH, et al: Statin therapy accelerate reendothelialization: a novel effect involving mobilization and incorporation of bone marrow-derived endothelial progenitor cells. Circulation 105: 3017-3024, 2002.
3. Assmus B, Schachinger V, Teupe C, et al: Transplantation of progenitor cells and regeneration enhancement in acute myocardial infarction (TOPCARE-AMI). Circulation 106: 3009-3017, 2002.
4. Hill JM, Zalos G, Halcox JP, Schenke WH, Waclawiw MA, Quyyumi AA and Finkel T: Circulating endothelial progenitor cells, vascular function, and cardiovascular risk. N Engl J Med 348: 593-600, 2003.
5. Vasa M, Fichtlscherer S, Aicher A, Adler K, Urbich C, Martin H, Zeiher AM and Dimmeler S: Number and migratory activity of circulating endothelial progenitor cells inversely correlate with risk factors for coronary artery disease. Circ Res 89: E1-E7, 2001.
6. Schmidt-Lucke C, Rossig L, Fichtlscherer S, et al: Reduced number of circulating endothelial progenitor cells predicts future cardiovascular events: proof of concept for the clinical importance of endogenous vascular repair. Circulation 111: 2981-2987, 2005.
7. Aicher A, Heeschen C, Mildner-Rihm C, Urbich C, Ihling C, Technau-Ihling K, Zeiher AM and Dimmeler S: Essential role of endothelial nitric oxide synthase for mobilization of stem and progenitor cells. Nat Med 9: 1370-1376, 2003.
8. Guthrie SM, Curtis LM, Mames RN, Simon GG, Grant MB and Scott EW: The nitric oxide pathway modulates hemangioblast activity of adult hematopoietic stem cells. Blood 105: 1916-1922, 2005.
9. Hiasa K, Ishibashi M, Ohtani K, et al: Gene transfer of stromal cell-derived factor-1 alpha enhances ischemic vasculogenesis and angiogenesis via vascular endothelial growth factor/endothelial nitric oxide synthase-related pathway: next-generation chemokine therapy for therapeutic neovascularization. Circulation 109: 2454-2461, 2004.
10. Vasa M, Fichtlscherer S, Adler K, Aicher A, Martin H, Zeiher AM and Dimmeler S: Increase in circulating endothelial progenitor cells by statin therapy in patients with stable coronary artery disease. Circulation 103: 2885-2890, 2001.
11. Lee DH and Goldberg AL: Proteasome inhibitors: Valuable new tools for cell biologists. Trends Cell Biol 8: 397-403, 1998.
12. Voorhees PM and Orlowski RZ: The proteasome and proteasome inhibitors in cancer therapy. Annu Rev Pharmacol Toxicol 46: 189-213, 2006.
13. Adams J: The proteasome A suitable antineoplastic target. Nat Rev Cancer 4: 349-360, 2004.
14. Meiners S, Ludwig A, Stangl V and Stangl K: Proteasome inhibitors: poisons and remedies. Med Res Rev 28: 309-327, 2008.
15. Stangl V, Lorenz M, Meiners S, Ludwig A, Bartsch C, Moobed M, Vietzke A, Kinkel HT, Baumann G and Stangl K: Long-term up-regulation of eNOS and improvement of endothelial function by inhibition of the ubiquitin-proteasome pathway. FASEB J 18: 272-279, 2004.
16. Meiners S, Ludwig A, Lorenz M, Dreger H, Baumann G, Stangl V and Stangl K: Nontoxic proteasome inhibition activates a protective antioxidant defense response in endothelial cells. Free Radic Biol Med 40: 2232-2241, 2006.
17. Drexler HC, Risau W and Konerding MA: Inhibition of proteasome function induces programmed cell death in proliferating endothelial cells. FASEB J 14: 65-77, 2000.
18. Wojcik C: Proteasomes in apoptosis: Villains or guardians? Cell Mol Life Sci 56: 908-917, 1999.
19. Chen JZ, Zhu JH, Wang XX, Zhu JH, Xie XD, Sun J, Shang YP, Guo XG, Dai HM and Hu SJ: Effects of homocysteine on number and activity of endothelial progenitor cells from peripheral blood. J Mol Cell Cardiol 36: 233-239, 2004.
20. Assmus B, Urbich C, Aicher A, et al: HMG-CoA reductase inhibitors reduce senescence and increase proliferation of endothelial progenitor cells via regulation of cell cycle regulatory genes. Circ Res 92: 1049-1055, 2003.
21. Zhu JH, Chen JZ, Wang XX, Xie XD, Sun J and Zhang FR: Homocysteine accelerates senescence and reduces proliferation of endothelial progenitor cells. J Mol Cell Cardiol 40: 648-652, 2006.
22. Liu X, Fan XL, Zhao Y, Luo GR, Li XP, Li R and Le WD: Estrogen provides neuroprotection against activated microglia-induced dopaminergic neuronal injury through both estrogen receptor-alpha and estrogen receptor-beta in microglia. J Neurosci Res 81: 653-665, 2005.
23. Herrmann J, Saguner AM, Versari D, Peterson TE, Chade A, Olson M, Lerman LO and Lerman A: Chronic proteasome inhibition contributes to coronary atherosclerosis. Circ Res 101: 865-874, 2007.
24. Kostin S, Pool L, Elsässer A, et al: Myocytes die by multiple mechanisms in failing human hearts. Circ Res 92: 715-724, 2003.
25. Pye J, Ardeshirpour F, McCain A, et al: Proteasome inhibition ablates activation of NF-kappa B in myocardial reperfusion and reduces reperfusion injury. Am J Physiol Heart Circ Physiol 284: H919-H926, 2003.
26. Meiners S, Laule M, Rother W, Guenther C, Prauka I, Muschick P, Baumann G, Kloetzel PM and Stangl K: Ubiquitin-proteasome pathway as a new target for the prevention of restenosis. Circulation 105: 483-489, 2002.
27. Depre C, Wang Q, Yan L, et al: Activation of the cardiac proteasome during pressure overload promotes ventricular hypertrophy. Circulation 114: 1821-1828, 2006.
28. Kisselev AF and Goldberg AL: Proteasome inhibitors: From research tools to drug candidates. Chem Biol 8: 739-758, 2001.
29. Veschini L, Belloni D, Foglieni C, Cangi MG, Ferrarini M, Caligaris-Cappio F and Ferrero E: Hypoxia-inducible transcription factor-1 alpha determines sensitivity of endothelial cells to the proteasome inhibitor bortezomib. Blood 109: 2565-2570, 2007.
30. Bross PF, Kane R, Farrell AT, et al: Approval summary for bortezomib for injection in the treatment of multiple myeloma. Clin Cancer Res 10: 3954-3964, 2004.
31. Chade AR, Herrmann J, Zhu X, Krier JD, Lerman A and Lerman LO: Effects of proteasome inhibition on the kidney in experimental hypercholesterolemia. J Am Soc Nephrol 16: 1005-1012, 2005.
32. Takaoka M, Itoh M, Kohyama S, Shibata A, Ohkita M and Matsumura Y: Proteasome inhibition attenuates renal endothelin-1 production and the development of ischemic acute renal failure in rats. J Cardiovasc Pharmacol 36: S225-S227, 2000.
33. Okamoto H, Takaoka M, Ohkita M, Itoh M, Nishioka M and Matsumura YA: proteasome inhibitor lessens the increased aortic endothelin-1 content in deoxycorticosterone acetate-salt hypertensive rats. Eur J Pharmacol 350: R11-R12, 1998.
34. Maki CG, Huibregtse JM and Howley PM: In vivo ubiquitination and proteasome-mediated degradation of p53. Cancer Res 56: 2649-2654, 1996.
35. Salghetti SE, Kim SY and Tansey WP: Destruction of Myc by ubiquitinmediated proteolysis: cancer-associated and transforming mutations stabilize Myc. EMBO J 18: 717-726, 1999.
36. Yang Y, Fang S, Jensen JP, Weissman AM and Ashwell JD: Ubiquitin protein ligase activity of IAPs and their degradation in proteasomes in response to apoptotic stimuli. Science 288: 874-877, 2000.
37. Ganten TM, Koschny R, Haas TL, Sykora J, Li-Weber M, Herzer K and Walczak H: Proteasome inhibition sensitizes hepatocellular carcinoma cells, but not human hepatocytes, to TRAIL. Hepatology 42: 588-597, 2005.
38. Govers R, Bree P and Rablink TJ: Involvement of the proteasome in activation of endothelial nitric oxide synthase. Life Sci 73: 2225-2236, 2003.
39. Wei Q and Xia Y: Proteasome inhibition down-regulates endothelial nitric-oxide synthase phosphorylation and function. J Biol Chem 281: 21652-21659, 2006.
40. Naujokat C and Saric T: Concise review: Role and function of the ubiquitin-proteasome system in mammalian stem and progenitor cells. Stem Cells 25: 2408-2418, 2007.
41. Naujokat C, Sezer O, Zinke H, Leclere A, Hauptmann S and Possinger K: Proteasome inhibitors induce caspase-dependent apoptosis and accumulation of p21WAF1/Cip1 in human immature leukemic cells. Eur J Haematol 65: 221-236, 2000.
42. Zavrski I, Naujokat C, Niemöller K, Jakob C, Heider U, Langelotz C, Fleissner C, Eucker J, Possinger K and Sezer O: Proteasome inhibitors induce growth inhibition and apoptosis in myeloma cell lines and in human bone marrow myeloma cells irrespective of chromosome 13 deletion. J Cancer Res Clin Oncol 129: 383-391, 2003.
43. Oikawa T, Sasaki T, Nakamura M, Shimanmura M, Tanahashi N, Omura S and Tanaka K: The proteasome is involved in angiogenesis. Biochem Biophys Res Commun 246: 243-248, 1998.
44. Roccaro AM, Hideshima T, Raje N, et al: Bortezomib mediates antiangiogenesis in multiple myeloma via direct and indirect effects on endothelial cells. Cancer Res 66: 184-191, 2006.
45. Asahara T, Takahashi T, Masuda H, Kalka C, Chen D, Iwaguro H, Inai Y, Silver M and Isner JM: VEGF contributes to postnatal neovascularization by mobilizing bone marrow-derived endothelial progenitor cells. EMBO J 18: 3964-3972, 1999.
46. Wijelath ES, Rahman S, Murray J, Patel Y, Savidge G and Sobel M: Fibronectin promotes VEGF-induced CD34 cell differentiation into endothelial cells. J Vasc Surg 39: 655-660, 2004.